semaglutide or tirzepatide

DRUG2 trials

Sponsors

Mayo Clinic, National and Kapodistrian University of Athens

Conditions

Anti-obesity AgentsMenopauseObesityObesity (Disorder)Precision Medicine

Phase 4

Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women

Enrolling by invitationNCT07057310

Mayo ClinicMenopause, Obesity

Start: 2025-05-01End: 2027-03-31Target: 30Updated: 2026-07-20

Unknown Phase

Precision Obesity Medicine: Genetic Prediction of Response to GLP-1/GIP Agonists.

RecruitingNCT07653412

National and Kapodistrian University of AthensAnti-obesity Agents, Obesity (Disorder), Precision Medicine

Start: 2026-04-22End: 2027-06-30Target: 220Updated: 2026-07-10